
A recent study, SoMOSA, explored predictors of improvement in severe asthma patients treated with omalizumab. The research involved 216 uncontrolled atopic asthmatics (GINA step 4/5) over one year. Initially, 63% showed early clinical improvement, while 69% later experienced reduced exacerbations, with 57% on mOCS achieving ≥50% dose reduction. Traditional biomarkers like blood and sputum eosinophils or exhaled nitric oxide did not forecast clinical response. However, specific breathomics and plasma lipid biomarkers showed promise, strongly predicting outcomes. These findings mark a crucial advancement, potentially enhancing treatment outcomes in severe asthma.
Like
Save
Share